China Shineway Pharmaceutical Group Limited Market Cap ($733.01 Million)
Market Cap & Net Worth: China Shineway Pharmaceutical Group Limited (C1S)
China Shineway Pharmaceutical Group Limited market cap. China Shineway Pharmaceutical Group Limited (F:C1S) has a market capitalization of $733.01 Million (€626.98 Million) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #9995 globally and #1216 in its home market, demonstrating a 1.84% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying China Shineway Pharmaceutical Group Limited's stock price €0.83 by its total outstanding shares 755400000 (755.40 Million). Also see C1S cash flow metrics for how efficiently the company converts equity into cash flow.
China Shineway Pharmaceutical Group Limited Market Cap History (2015–2026)
China Shineway Pharmaceutical Group Limited market cap history from 2015 to 2026. Data shows growth from $9.45 Million to $733.01 Million (48.44% CAGR). Check C1S stock price and chart for real-time trading data and today's change.
China Shineway Pharmaceutical Group Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how China Shineway Pharmaceutical Group Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore China Shineway Pharmaceutical Group Limi (C1S) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.25x
China Shineway Pharmaceutical Group Limited's market cap is 0.25 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.84x
China Shineway Pharmaceutical Group Limited's market cap is 0.84 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $11.30 Million | $1.99 Billion | $589.20 Million | 0.01x | 0.02x |
| 2017 | $11.13 Million | $1.92 Billion | $451.55 Million | 0.01x | 0.02x |
| 2018 | $16.16 Million | $2.57 Billion | $505.88 Million | 0.01x | 0.03x |
| 2019 | $22.61 Million | $2.71 Billion | $503.15 Million | 0.01x | 0.04x |
| 2020 | $25.43 Million | $2.66 Billion | $295.03 Million | 0.01x | 0.09x |
| 2021 | $91.05 Million | $3.22 Billion | $556.67 Million | 0.03x | 0.16x |
| 2022 | $220.17 Million | $3.95 Billion | $722.77 Million | 0.06x | 0.30x |
| 2023 | $365.71 Million | $4.52 Billion | $969.51 Million | 0.08x | 0.38x |
| 2024 | $1.02 Billion | $3.78 Billion | $840.05 Million | 0.27x | 1.22x |
| 2025 | $794.83 Million | $3.14 Billion | $949.95 Million | 0.25x | 0.84x |
Competitor Companies of C1S by Market Capitalization
Companies near China Shineway Pharmaceutical Group Limited in the global market cap rankings as of November 4, 2026. Also see C1S total asset value for a full breakdown of the balance sheet.
Key companies related to China Shineway Pharmaceutical Group Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #516 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #591 globally with a market cap of $45.45 Billion USD ( CN¥310.59 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #516 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.55 |
| #591 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.45 Billion | CN¥48.69 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of China Shineway Pharmaceutical Group Limited (2015–2026)
Market capitalization of China Shineway Pharmaceutical Group Limited from 2015 to today. Between 2015 and today, China Shineway Pharmaceutical Group Limited's market cap moved from $9.45 Million to $ 733.01 Million, with a yearly change of 48.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €733.01 Million | -7.78% |
| 2025 | €794.83 Million | -22.41% |
| 2024 | €1.02 Billion | +180.13% |
| 2023 | €365.71 Million | +66.11% |
| 2022 | €220.17 Million | +141.80% |
| 2021 | €91.05 Million | +257.99% |
| 2020 | €25.43 Million | +12.50% |
| 2019 | €22.61 Million | +39.89% |
| 2018 | €16.16 Million | +45.24% |
| 2017 | €11.13 Million | -1.56% |
| 2016 | €11.30 Million | +19.63% |
| 2015 | €9.45 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of China Shineway Pharmaceutical Group Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $733.01 Million USD |
| MoneyControl | $733.01 Million USD |
| MarketWatch | $733.01 Million USD |
| marketcap.company | $733.01 Million USD |
| Reuters | $733.01 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese pharmaceutical products in the People's Republic of China and Hong Kong. The company offers Chinese medicines in the form of injection, soft capsules, and granules; tablets, pills, oral liquid, and powder; and traditional Chinese medicine granules … Read more